News Formal

Wells Fargo becomes bullish on this biotech company

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 72%

Health Care Industry Nyheter

Neurocrine Biosciences Inc,Wells Fargo & Co,Stock Markets

Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday's close. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.

"We think Crinecerfont is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Elsewhere in the company's pipeline, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opoprtunity.

 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 12. in SE

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

S&P 500 target raised to 5500+ at Wells Fargo on strong earnings growthS&P 500 target raised to 5500+ at Wells Fargo on strong earnings growth
Källa: Investingcom - 🏆 450. / 53 Läs mer »